Co-Diagnostics Stock Forecast, Price & News

Co-Diagnostics (NASDAQ:CODX) Frequently Asked Questions

Is Co-Diagnostics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Co-Diagnostics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Co-Diagnostics stock.
View analyst ratings for Co-Diagnostics or view top-rated stocks.

How has Co-Diagnostics' stock been impacted by Coronavirus (COVID-19)?

Co-Diagnostics' stock was trading at $13.19 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CODX stock has decreased by 37.4% and is now trading at $8.26.
View which stocks have been most impacted by COVID-19.

When is Co-Diagnostics' next earnings date?

Co-Diagnostics is scheduled to release its next quarterly earnings announcement on Thursday, March 24th 2022.
View our earnings forecast for Co-Diagnostics.

How were Co-Diagnostics' earnings last quarter?

Co-Diagnostics, Inc. (NASDAQ:CODX) announced its quarterly earnings data on Thursday, November, 11th. The company reported $0.38 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.21 by $0.17. The business earned $30.10 million during the quarter, compared to analyst estimates of $24 million. Co-Diagnostics had a trailing twelve-month return on equity of 50.81% and a net margin of 40.11%. During the same period in the prior year, the company earned $0.53 EPS.
View Co-Diagnostics' earnings history.

What guidance has Co-Diagnostics issued on next quarter's earnings?

Co-Diagnostics issued an update on its FY 2021 earnings guidance on Thursday, December, 9th. The company provided earnings per share (EPS) guidance of $1.070-$1.160 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.980. The company issued revenue guidance of $96 million-$100 million, compared to the consensus revenue estimate of $95.21 million.

What price target have analysts set for CODX?

4 Wall Street analysts have issued 1-year price objectives for Co-Diagnostics' stock. Their forecasts range from $14.00 to $15.00. On average, they anticipate Co-Diagnostics' stock price to reach $14.50 in the next year. This suggests a possible upside of 75.5% from the stock's current price.
View analysts' price targets for Co-Diagnostics or view top-rated stocks among Wall Street analysts.

Who are Co-Diagnostics' key executives?

Co-Diagnostics' management team includes the following people:

• Dwight Howard Egan, Chairman, President & Chief Executive Officer
• Brian L. Brown, Chief Financial Officer & Secretary
• Jesse Montgomery, Chief Scientific Officer
• Reed L. Benson, General Counsel (LinkedIn Profile)

Who are some of Co-Diagnostics' key competitors?

Some companies that are related to Co-Diagnostics include Cerus (CERS), Intersect ENT (XENT), Pulmonx (LUNG), Inovio Pharmaceuticals (INO), AngioDynamics (ANGO), Longview Acquisition Corp. II (LGV), Procept BioRobotics (PRCT), Cardiovascular Systems (CSII), SI-BONE (SIBN), Sight Sciences (SGHT), CryoLife (CRY), Orthofix Medical (OFIX), OraSure Technologies (OSUR), Surmodics (SRDX) and Antares Pharma (ATRS).
View all of CODX's competitors.

What other stocks do shareholders of Co-Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Co-Diagnostics investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Moderna (MRNA), Vaxart (VXRT), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), iBio (IBIO), Advanced Micro Devices (AMD), Pfizer (PFE) and Johnson & Johnson (JNJ).

When did Co-Diagnostics IPO?

(CODX) raised $9 million in an IPO on Thursday, July 13th 2017. The company issued 1,300,000 shares at a price of $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities served as the underwriters for the IPO.

What is Co-Diagnostics' stock symbol?

Co-Diagnostics trades on the NASDAQ under the ticker symbol "CODX."

Who are Co-Diagnostics' major shareholders?

Co-Diagnostics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include UMA Financial Services Inc. (0.12%). Company insiders that own Co-Diagnostics stock include Dwight H Egan, Eugene Durenard, Reed L Benson and Richard S Serbin.
View institutional ownership trends for Co-Diagnostics.

Which major investors are buying Co-Diagnostics stock?

CODX stock was bought by a variety of institutional investors in the last quarter, including UMA Financial Services Inc..
View insider buying and selling activity for Co-Diagnostics or or view top insider-buying stocks.

How do I buy shares of Co-Diagnostics?

Shares of CODX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Co-Diagnostics' stock price today?

One share of CODX stock can currently be purchased for approximately $8.26.

How much money does Co-Diagnostics make?

Co-Diagnostics has a market capitalization of $238.63 million and generates $74.55 million in revenue each year. The company earns $42.48 million in net income (profit) each year or $1.40 on an earnings per share basis.

How many employees does Co-Diagnostics have?

Co-Diagnostics employs 37 workers across the globe.

What is Co-Diagnostics' official website?

The official website for Co-Diagnostics is www.codiagnostics.com.

Where are Co-Diagnostics' headquarters?

Co-Diagnostics is headquartered at 2401 SOUTH FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT, 84124.

How can I contact Co-Diagnostics?

Co-Diagnostics' mailing address is 2401 SOUTH FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT, 84124. The company can be reached via phone at (801) 438-1036 or via email at [email protected].